Company profile

Fujifilm Pharmaceuticals U.S.A., Inc.

Privately held: no public share price (Wholly-owned US subsidiary of FUJIFILM Holdings America, itself a subsidiary of Tokyo-listed FUJIFILM Holdings; the subsidiary has no separate listed equity. Parent: Fujifilm Holdings Corporation (TSE 4901). [resolved 2026-08-05 by resolve-null-is-public; source: https://www.fujifilm.com/us/en/about/region/affiliates]) · United States

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
ribonucleotide reductase / DNA polymerase (dCTP competition)Small molecule
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.